Capital A Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Capital A Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$3.2K	Buy	+26	New	+$2.82K	0.04%	276

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Capital A Wealth Management's JAZZ Position: Q2 2025 in Review

Capital A Wealth Management opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2025: 26 shares worth $3.2K. The stake represents 0.04% of the portfolio and ranks #276 among its holdings.

501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

Capital A Wealth Management held 26 shares of Jazz Pharmaceuticals worth $3.2K as of Q2 2025.
Jazz Pharmaceuticals was a new Capital A Wealth Management position in Q2 2025.
Jazz Pharmaceuticals made up 0.04% of Capital A Wealth Management's portfolio in Q2 2025, its #276 holding.
501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Capital A Wealth Management's 13F filing for Q2 2025, filed 26 Sep 2025.